Sareum
Holdings PLC
("Sareum"
or the "Company")
New Patent Allowance
Cambridge, UK,
15 March 2024 - Sareum Holdings plc (AIM:
SAR), a clinical-stage biotechnology company
developing next-generation kinase inhibitors for autoimmune disease
and cancer, today announces that the European Patent
Office has issued a Notice of Allowance for a patent relating to
SDC‐1801, the Company's lead TYK2/JAK1 kinase inhibitor, currently
in clinical development in Australia.
The newly approved European patent application,
EP3864009, safeguards SDC‐1801, its medical applications
particularly in the treatment of autoimmune diseases, and certain
methods of synthesis.
This follows approvals in 2023 by the China
National Intellectual Property Administration, and the Japan Patent
Office for the same protections.
Patent applications in the US (US2021387981)
and other territories are still under review.
The Company expects that the patent will be
granted in the near future, subject to certain formalities being
completed.
Dr John
Reader, Sareum's Chief Scientific Officer,
commented: "This new patent allows us to enhance our
intellectual property portfolio in a crucial market. Our Phase 1a
trial for SDC-1801 in Australia is progressing smoothly, with the
Single Ascending Dose (SAD) and Food Effect study revealing no
significant adverse events. This progress highlights the potential
of SDC-1801 to achieve therapeutic drug levels in the bloodstream
through once-daily oral dosing."
- Ends -
For further
information, please contact:
|
Sareum Holdings plc
Tim Mitchell, CEO
Lauren Williams, Head of Investor
Relations
|
01223 497700
ir@sareum.co.uk
|
|
Strand Hanson Limited (Nominated
Adviser)
James Dance / James
Bellman
|
020 7409 3494
|
|
Peel Hunt LLP (Joint Corporate
Broker)
James Steel / Patrick Birkholm
|
020 7418 8900
|
|
Hybridan LLP (Joint Corporate
Broker)
Claire Noyce
|
020 3764 2341
|
|
ICR Consilium (Financial PR)
Jessica Hodgson / Davide Salvi /
Kumail Waljee
|
0203 709 5700
|
The information contained within this announcement is deemed
by the Company to constitute inside information as stipulated under
the Market Abuse Regulation (EU) No. 596/2014 as it forms part of
United Kingdom domestic law by virtue of the European Union
(Withdrawal) Act 2018, as amended by virtue of the Market Abuse
(Amendment) (EU Exit) Regulations 2019 ("UK
MAR").
About
Sareum
Sareum Holdings (AIM:SAR) is a
clinical-stage biotechnology company
developing next generation kinase inhibitors for autoimmune disease
and cancer.
The Company is focused on developing
next generation small molecules which modify the activity of the
JAK kinase family and have best-in-class potential. Its lead
candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1.
SDC-1801 is a potential treatment for a range of autoimmune
diseases and has entered Phase 1a/b clinical development with an
initial focus on psoriasis.
Sareum is also developing SDC-1802,
a TYK2/JAK1 inhibitor with a potential application for cancer
immunotherapy.
Sareum Holdings plc is based in
Cambridge, UK, and is listed on the AIM market of the London Stock
Exchange, trading under the ticker SAR. For further information,
please visit the Company's website at www.sareum.com